Stockpolly
Search
CNTB · NASDAQ · Biotechnology

Connect Biopharma (ADR) (CNTB)

Develops rademikibart for asthma and COPD outside Greater China.

$2.80
Pre-market+0.03 (+1.27%)
At close$2.77(+17.16%)
Watchlist

In millions of USD, except per-share figures

In millionsQ4 FY20Dec 2020Q2 FY21Jun 2021Q4 FY21Dec 2021Q2 FY22Jun 2022Q4 FY22Dec 2022Q2 FY23Jun 2023Q4 FY23Dec 2023Q2 FY24Jun 2024Q4 FY24Dec 2024Q2 FY25Jun 2025Q4 FY25Dec 2025Q2 FY26Jun 2026
Revenue0000000241003
Cost of revenue000011000000
Gross profit0000−1−10241003
04158605434371010131640
Research & development03447514527265691116
07111198854544
Selling & marketing0711098000000
General & administrative0001100854544
Other expenses000−2003000020
Operating income0−41−58−60−54−35−3714−10−13−16−37
21−10520−24511101
Interest income000012−214120
Interest expense000000000000
Other non-operating income−1−21−212−4−1−1−1−100
Income before tax0−146−56−60−56−31−3215−9−13−15−37
Income tax expense000000000000
Net income from continuing operations−108−146−57−60−57−31−3215−9−13−15−37
Other adjustments10800000000000
Net income0−146−57−60−57−31−3215−9−13−15−37
EPS, basic−$0.00−$3.10−$1.05−$13.47−$1.03−$0.56−$0.52$0.14−$0.42−$0.23−$0.27−$0.61
EPS, diluted−$0.00−$3.10−$1.05−$13.47−$1.03−$0.56−$0.52$0.14−$0.42−$0.23−$0.27−$0.61
Weighted average shares, basic554754555555555555555663
Weighted average shares, diluted554754555555555655555663
EBITDA−20−20−56−61−56−30−3515−9−13−15−37
Depreciation & amortization000011000000
EBIT−20−21−56−61−56−31−3615−9−13−15−37